Evidence map›Paper›PMID 18330934›Full record

ReviewWorld journal of gastroenterology2008

H pylori recurrence after successful eradication.

Yaron Niv

Registry-linked trialOpen access · hybridAbstract readEditorialReview
In one paragraph

Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05861687 (Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05861687 phase2 / phase3completednot on this mapstarted 2021, after this paper: background citation

Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials

TypeinterventionalSponsorFinni KollinsRan2021 to 2022Enrolled51ConditionsHelicobacter Pylori InfectionArmsEsomeprazole, Lansoprazole, Amoxicillin, Clarithromycin
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood.Pediatrics international : official journal of the Japan Pediatric Society · 2020
    Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2011
    Trial
  6. Effect of nonsurgical periodontal therapy on the eradication of gastricJournal of advanced periodontology & implant dentistry · 2025
    Article
  7. Therapeutics and clinical risk management · 2025
    Review
  8. Article
  9. Prevalence of OralClinical and experimental gastroenterology · 2023
    Article
  10. Review
  11. Article
  12. Epidemiological Profile ofJournal of epidemiology and global health · 2020
    Article
  13. Dentists Are at a Higher Risk for OralBioMed research international · 2020
    Article
  14. Article
  15. Common Variable Immunodeficiency and Gastric Malignancies.International journal of molecular sciences · 2018
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Quality of healing of gastric ulcers: Natural products beyond acid suppression.World journal of gastrointestinal pathophysiology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Yaron Niv
Clalit Health Services · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrence of H pylori after eradication is rare in developed countries and more frequent in developing countries. Recrudescence (recolonization of the same strain within 12 mo after eradication) rather than reinfection (colonization with a new strain, more than 12 mo after eradication) is considered to be responsible for most of the cases. This observation was confirmed only in developed countries, while in developing countries a recent meta-analysis demonstrated a high rate of reinfection. The proportion of H pylori annual recurrence was 2.67% and 13.00% in developed and developing countries, respectively. Nested meta-analysis (only cases with a longer follow-up and a negative (13)CUBT a year after eradication) revealed annual recurrence rate of 1.45% [relative risk (RR), 0.54] and 12.00% (RR, 0.92) in developed and developing countries, respectively. These findings support the notion that in developed countries many cases of recurrence are due to recrudescence within the first year after eradication, with a 46% drop in the recurrence rate after the first year post eradication, while in developing countries reinfection is more pronounced, and continue at the same rate since eradication. A different approach for follow-up after H pylori eradication is probably needed in patients of developing countries, since reinfection is highly prevalent.

Indexed as

AnimalsDeveloped CountriesDeveloping CountriesHelicobacter InfectionsHelicobacter pyloriHumansMeta-Analysis as TopicPrevalenceSecondary Prevention

Identifiers

PMID18330934
PMCPMC2693738
OpenAlexW2105247714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.